Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
|Articles|April 6, 2019
The ID Pipeline: FDA Activity from the Week of March 31, 2019
Author(s)Contagion® Editorial Staff
Here is a look at infectious disease related US Food and Drug Administration news from the week of March 31, 2019.
Advertisement
Here is a look at infectious disease related US Food and Drug Administration (FDA) news from the week of March 31, 2019.
Gilead Submits Supplemental NDA for Descovy for PrEP
On Friday, April 5, 2019, Gilead Sciences, Inc. submitted a supplemental new drug application to the US Food and Drug Administration (FDA) for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for HIV pre-exposure prophylaxis (PrEP).
The announcement comes a month after Gilead presented data from the phase 3
“Data have shown that when used in combination with other agents for HIV treatment, Descovy offers high efficacy and additional benefits with respect to renal and bone safety compared with Truvada. Now, the results from the DISCOVER trial suggest that Descovy may offer those same benefits for HIV prevention, which are important considerations for the potential long-term use of PrEP,” John McHutchison, AO, MD, chief scientific officer and head of Research and Development at Gilead, said in a company statement. “We look forward to working with the FDA to help evaluate bringing this option to people at risk of acquiring HIV infection.”
Descovy is approved in the United States for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients weighing at least 35 kg, but it does not currently include a PrEP indication.
A priority review voucher was submitted with the filing. The anticipated review time is 6 months.
The full press release is available
Entasis Therapeutics Launches Global Phase 3 Trial of ETX2514SUL for Infections Caused by Carbapenem-Resistant Acinetobacter
On Thursday, April 4, 2019, Entasis Therapeutics announced the launch of the ATTACK phase 3 pivotal clinical trial to evaluate ETX2514SUL, a fixed-dose combination of its broad-spectrum β-lactamase inhibitor ETX2514 with sulbactam. ETX2514SUL is used to treat patients with penumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii, which currently has very limited therapeutic options because of its multidrug resistance.
The 2-part trial (Acinetobacter Treatment Trial Against Colistin) will enroll a total of 300 patients from 18 countries, and Entasis is optimistic that results will be sufficient to support the filing of a new drug application with regulatory authorities in both the US and Europe.
"We are excited to initiate our global ATTACK clinical trial with the ultimate goal of obtaining regulatory approval in the US and other countries,” Manos Perros, CEO of Entasis Therapeutics, said in a company statement. “It is the culmination of extensive preclinical development and multiple Phase 1 and 2 clinical trials, which have shown that ETX2514SUL has great potential for the treatment of patients with carbapenem-resistant A baumannii infections. We are fully funded through this study and look forward to reporting top-line data in the second half of 2020.”
ETX2514SUL has been granted a Qualified Infectious Disease Product and Fast Track designation by the US Food and Drug Administration.
The full press release is available
Advertisement
Related to this article
Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Advertisement
Advertisement
Trending on Contagion Live
1
How The Food Safety Surveillance Infrastructure Works in the US
2
Evaluating Ebola Vaccine Against Current Bundibugyo Species
3
Ebola and the Ongoing Tale of US Failures
4
Implanted Antibiotic Reduced Systemic Regimen for Orthopedic Infection
5